#分享美股交易赢英伟达股票 Based on the U.S. stock market data and publicly available information as of Wednesday, June 3, 2026, here is the trend analysis of some U.S. stocks:

1 NVIDIA (NVDA)
Closed down 3.62%, at $214.75, breaking below the 21-day moving average, retracing 7.5% from Tuesday's high during the day.
Technical indicators show a correction phase, with short-term support in the $200-$210 range; a break below could lead to further decline.
2 Microsoft (MSFT)
Fell 3.17%, at $427.34, breaking below the 200-day moving average, with medium- to long-term trend under pressure.
After-hours earnings reports show revenue growth but with slowing momentum, increasing market concerns over AI capital expenditure, likely leading to continued short-term volatility.
3 Amazon (AMZN)
Fell 2.53%, at $250.02, in a secondary correction phase, with the short-term trendline broken, and the long-term trendline near $246.
Need to watch if the $240-$250 range can stabilize; a break above $250 could trigger a new rally.
4 Meta (META)
Contrary to the trend, rose 4.24%, at $622.98, breaking through the short-term trendline, but the long-term trendline is near $640.
If it can hold above $620 and break through $640, further upside is possible; otherwise, it may retest support at $600.
5 IBM (IBM)
Fell 7.2%, at $305.63, with volume surging 73%, showing classic warning signals on the technical front, likely to continue declining in the short term.
Watch the $300 support level; a break below could lead to a test of $290.
6 Eli Lilly (LLY)
Rose 1.4%, at $1,078.78, breaking above the high handle-downtrend, signaling early buy opportunities.
Technical indicators show a bullish alignment, with potential for further gains toward $1,100.
7 Neurocrine Biosciences (NBIX)
Jumped 6.6%, at $165.11, re-establishing above the $160.18 cup-and-handle buy point.
If it can hold above $165, a new rally could begin, targeting $170.
8 TG Therapeutics (TGTX)
Rose 9.5%, at $40.11, rebounding directly from the 50-day moving average, driven by positive data on new multiple sclerosis drugs.
Short-term strength is evident; watch if the $40-$42 range can be broken through.
Overall, major tech giants are generally correcting, biotech sectors are defying the trend and gaining strength, and energy sectors are performing well due to rising oil prices. The market may enter a high-level consolidation phase in the short term, with attention needed on earnings reports, geopolitical developments, and inflation expectations impacting individual stocks.$NVDA $IBM ‌ ‌